Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. Soluble Urokinase Receptor (SuPAR) in COVID-19-Related AKI

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Authors' Reply

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  3. Assessment of Perfusion and Oxygenation of the Human Renal Cortex and Medulla by Quantitative MRI during Handgrip Exercise

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Diagnostic and prognostic value of the electrocardiogram in stable outpatients with type 2 diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Glenn Chertow
  • Priya Vart
  • Niels Jongs
  • Robert Toto
  • Jose Luis Gorriz
  • Fan Fan Hou
  • John McMurray
  • Ricardo Correa-Rotter
  • Peter Rossing
  • C David Sjöström
  • Bergur Stefánsson
  • Anna Maria Langkilde
  • David Wheeler
  • Hiddo Heerspink
Vis graf over relationer

BACKGROUND: In the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized, placebo-controlled trial, the sodium-glucose cotransporter 2 inhibitor dapagliflozin significantly reduced risk of kidney failure and prolonged survival in patients with CKD with or without type 2 diabetes.

METHODS: Adults with eGFR of 25-75 ml/min per 1.73 m2 and urinary albumin-to-creatinine ratio of 200-5000 mg/g had been randomized to receive dapagliflozin 10 mg/d or placebo. Here, we conducted a prespecified analysis of dapagliflozin's effects in patients with stage 4 CKD (eGFR,30 ml/min per 1.73 m2) at baseline. The primary end point was a composite of time to ≥50% sustained decline in eGFR, ESKD, or kidney or cardiovascular death. Secondary end points were a kidney composite (same as the primary end point but without cardiovascular death), a composite of cardiovascular death or heart failure hospitalization, and all-cause death.

RESULTS: A total of 293 participants with stage 4 CKD received dapagliflozin and 331 received placebo. Patients with stage 4 CKD randomized to dapagliflozin experienced a 27% (95% confidence interval [95% CI]: -2 to 47%) reduction in the primary composite endpoint, and 29% (-2 to 51%), 17% (-53 to 55%), and 32% (-21 to 61%) reductions in the kidney, cardiovascular and mortality endpoints, respectively, relative to placebo. Interaction P-values were 0.22, 0.13, 0.63, and 0.95, respectively, comparing CKD stages 4 versus 2/3. The eGFR slope declined by 2.15 and 3.38 ml/min per 1.73 m2 per year in the dapagliflozin and placebo groups, respectively (P=0.005). Patients treated with dapagliflozin or placebo had similar rates of serious adverse events and adverse events of interest.

CONCLUSIONS: Among patients with stage 4 CKD and albuminuria, the effects of dapagliflozin were consistent with those observed in the DAPA-CKD trial overall, with no evidence of increased risks.

TidsskriftJournal of the American Society of Nephrology : JASN
Udgave nummer9
Sider (fra-til)2352-2361
Antal sider10
StatusUdgivet - sep. 2021

ID: 66942913